The CD70-CD27 axis in oncology: the new kids on the block

The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. This is in contrast to physiologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Flieswasser, Tal, Van den Eynde, Astrid, Van Audenaerde, Jonas, De Waele, Jorrit, Lardon, Filip, Riether, Carsten, de Haard, Hans, Smits, Evelien, Pauwels, Patrick, Jacobs, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734249/
https://www.ncbi.nlm.nih.gov/pubmed/34991665
http://dx.doi.org/10.1186/s13046-021-02215-y
_version_ 1784627977154199552
author Flieswasser, Tal
Van den Eynde, Astrid
Van Audenaerde, Jonas
De Waele, Jorrit
Lardon, Filip
Riether, Carsten
de Haard, Hans
Smits, Evelien
Pauwels, Patrick
Jacobs, Julie
author_facet Flieswasser, Tal
Van den Eynde, Astrid
Van Audenaerde, Jonas
De Waele, Jorrit
Lardon, Filip
Riether, Carsten
de Haard, Hans
Smits, Evelien
Pauwels, Patrick
Jacobs, Julie
author_sort Flieswasser, Tal
collection PubMed
description The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. This is in contrast to physiological conditions, where tightly controlled expression of CD70 and CD27 plays a role in co-stimulation in immune responses. In hematological malignancies, cancer cells co-express CD70 and CD27 promoting stemness, proliferation and survival of malignancy. In solid tumors, only expression of CD70 is present on the tumor cells which can facilitate immune evasion through CD27 expression in the tumor microenvironment. The discovery of these tumor promoting and immunosuppressive effects of the CD70-CD27 axis has unfolded a novel target in the field of oncology, CD70. In this review, we thoroughly discuss current insights into expression patterns and the role of the CD70-CD27 axis in hematological and solid malignancies, its effect on the tumor microenvironment and (pre)clinical therapeutic strategies.
format Online
Article
Text
id pubmed-8734249
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87342492022-01-07 The CD70-CD27 axis in oncology: the new kids on the block Flieswasser, Tal Van den Eynde, Astrid Van Audenaerde, Jonas De Waele, Jorrit Lardon, Filip Riether, Carsten de Haard, Hans Smits, Evelien Pauwels, Patrick Jacobs, Julie J Exp Clin Cancer Res Review The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. This is in contrast to physiological conditions, where tightly controlled expression of CD70 and CD27 plays a role in co-stimulation in immune responses. In hematological malignancies, cancer cells co-express CD70 and CD27 promoting stemness, proliferation and survival of malignancy. In solid tumors, only expression of CD70 is present on the tumor cells which can facilitate immune evasion through CD27 expression in the tumor microenvironment. The discovery of these tumor promoting and immunosuppressive effects of the CD70-CD27 axis has unfolded a novel target in the field of oncology, CD70. In this review, we thoroughly discuss current insights into expression patterns and the role of the CD70-CD27 axis in hematological and solid malignancies, its effect on the tumor microenvironment and (pre)clinical therapeutic strategies. BioMed Central 2022-01-06 /pmc/articles/PMC8734249/ /pubmed/34991665 http://dx.doi.org/10.1186/s13046-021-02215-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Flieswasser, Tal
Van den Eynde, Astrid
Van Audenaerde, Jonas
De Waele, Jorrit
Lardon, Filip
Riether, Carsten
de Haard, Hans
Smits, Evelien
Pauwels, Patrick
Jacobs, Julie
The CD70-CD27 axis in oncology: the new kids on the block
title The CD70-CD27 axis in oncology: the new kids on the block
title_full The CD70-CD27 axis in oncology: the new kids on the block
title_fullStr The CD70-CD27 axis in oncology: the new kids on the block
title_full_unstemmed The CD70-CD27 axis in oncology: the new kids on the block
title_short The CD70-CD27 axis in oncology: the new kids on the block
title_sort cd70-cd27 axis in oncology: the new kids on the block
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734249/
https://www.ncbi.nlm.nih.gov/pubmed/34991665
http://dx.doi.org/10.1186/s13046-021-02215-y
work_keys_str_mv AT flieswassertal thecd70cd27axisinoncologythenewkidsontheblock
AT vandeneyndeastrid thecd70cd27axisinoncologythenewkidsontheblock
AT vanaudenaerdejonas thecd70cd27axisinoncologythenewkidsontheblock
AT dewaelejorrit thecd70cd27axisinoncologythenewkidsontheblock
AT lardonfilip thecd70cd27axisinoncologythenewkidsontheblock
AT riethercarsten thecd70cd27axisinoncologythenewkidsontheblock
AT dehaardhans thecd70cd27axisinoncologythenewkidsontheblock
AT smitsevelien thecd70cd27axisinoncologythenewkidsontheblock
AT pauwelspatrick thecd70cd27axisinoncologythenewkidsontheblock
AT jacobsjulie thecd70cd27axisinoncologythenewkidsontheblock
AT flieswassertal cd70cd27axisinoncologythenewkidsontheblock
AT vandeneyndeastrid cd70cd27axisinoncologythenewkidsontheblock
AT vanaudenaerdejonas cd70cd27axisinoncologythenewkidsontheblock
AT dewaelejorrit cd70cd27axisinoncologythenewkidsontheblock
AT lardonfilip cd70cd27axisinoncologythenewkidsontheblock
AT riethercarsten cd70cd27axisinoncologythenewkidsontheblock
AT dehaardhans cd70cd27axisinoncologythenewkidsontheblock
AT smitsevelien cd70cd27axisinoncologythenewkidsontheblock
AT pauwelspatrick cd70cd27axisinoncologythenewkidsontheblock
AT jacobsjulie cd70cd27axisinoncologythenewkidsontheblock